Singapore markets closed

CytomX Therapeutics Inc (6C1.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
1.7560+0.0560 (+3.29%)
At close: 07:08PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
119,178
101,214
53,163
37,312
68,427
-
Operating expenses
Research development
78,557
77,680
111,649
114,194
112,936
-
Selling general and administrative
29,795
30,018
42,849
39,160
36,031
-
Total operating expenses
108,352
107,698
154,498
153,354
148,967
-
Operating income or loss
10,826
-6,484
-101,335
-116,042
-80,540
-
Interest expense
-
-
-
-
-
0
Total other income/expenses net
-56
-30
340
-83
-27
-
Income before tax
20,474
3,323
-99,317
-115,870
-78,731
-
Income tax expense
3,941
3,892
0
0
-13,911
-
Income from continuing operations
16,533
-569
-99,317
-115,870
-64,820
-
Net income
16,533
-569
-99,317
-115,870
-64,820
-
Net income available to common shareholders
16,533
-569
-99,317
-115,870
-64,820
-
Basic EPS
-0.15
-
-1.51
-1.81
-1.40
-2.93
Diluted EPS
-0.15
-
-1.51
-1.81
-1.40
-2.93
Basic average shares
69,945
-
65,740
64,147
46,146
45,336
Diluted average shares
69,945
-
65,740
64,147
46,146
45,336